Thank you for your email.
The Medicines Supply Team at the Department of Health and Social Care (DHSC) is aware that there have been recent
supply issues affecting some brands of adrenaline auto-injectors (AAI). DHSC worked closely with the MHRA,
NHS England, National experts and Patient groups and issued advice on management options to the NHS to ensure patients continued to be managed appropriately during that time.
As you are aware, in the UK there are three available brands of AAI devices available, EpiPen, Jext and Emerade.
The different brands of adrenaline auto-injectors are not used in exactly the same way and therefore specific training and advice is required for each of the devices.
We have been in contact with ALK-Abello Ltd, the UK supplier of Jext, who have confirmed they currently have supplies
of the 150 microgram and 300 microgram pens available.
It may be helpful to know that Mylan, the UK supplier of EpiPen, can confirm that the supply situation has much improved
and supplies of EpiPen Junior (150microgram) and EpiPen adult (300 microgram) are currently available in volumes that
are sufficient to meet normal UK requirements.EpiPen Junior and Epipen Adult are currently on a prescription validation
protocol. The prescription validation protocol means that pharmacies will need to order an EpiPen when presented with a
prescription and ensures supplies are managed equitably.
We are aware of a short-term supply issue currently affecting some Emerade devices, supplied by Bausch and
Lomb UK Ltd. This issue has been caused by manufacturing issues at their Swedish manufacturing partner, relating to
the production line, which has led to a temporary decrease in output. Limited supplies of Emerade 150 microgram pens
are currently available, however, Emerade 300 microgram and 500 microgram pens remain out of stock. Bausch and
Lomb expect supplies of Emerade 500 microgram to be available w/c 23rd September and supplies of
Emerade 300 microgram to be available early October.
Comprehensive guidance was issued to healthcare professionals to advise on the clinical management options during
this time (see link below).
DHSC continues to closely monitor the supply position for all AAI's to ensure that patients can continue to receive the treatment that they need and current supplies are sufficient to meet normal UK requirements.
I hope this is helpful.